You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities

A new report from Partnership for Health Analytic Research or PHAR describes how value assessments that use traditional cost-effectiveness analyses can overlook important health disparities and risk...
Read More
PhRMA presents research at ISPOR 2022

Last week at the ISPOR annual international meeting, PhRMA partnered with multiple organizations committed to advancing value assessment research and methods. We worked with a range of academics,...
Read More
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs

According to a recent survey by Verpora that will be presented this week at ISPOR, nearly half of U.S. payers surveyed expressed a belief that wider implementation of innovative contracts could lead...
Read More
Growth in innovative, value-based contracts holds promise for the health system and for patients

The extraordinary financial pressure COVID-19 is creating for the U.S. economy underscores the need for a renewed push toward a more value-driven health care system that prioritizes patient access...
Read More
Innovative contracts drive access for patients and value for the system

Our health care system is far from perfect, but there are solutions that will help address patient affordability concerns without sacrificing innovation, access or quality of care. For example,...
Read More
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

Value-based programs between biopharmaceutical companies and pharmacy benefit manager Express Scripts saved $4.3 billion on medicines last year. Patients in these plans with innovative contracting...
Read More
Low-value health care costs $345B each year and provides little benefit

Low-value health care is treatment that offers little to no clinical benefit to patients yet is a major drain of resources often at the detriment to patients. Low-value health care is one of the...
Read More
Addressing barriers that inhibit value-based contracts

With 56 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2019 and over 8,000 medicines in development around the globe, innovative medicines are transforming the way we treat...
Read More
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....
Read More